What is HC Wainwright’s Estimate for Nicox FY2026 Earnings?

Nicox SA (OTCMKTS:NICXF) – Equities researchers at HC Wainwright upped their FY2026 earnings estimates for Nicox in a note issued to investors on Tuesday, January 6th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.15 per share for the year, up from their previous forecast of $0.12. HC Wainwright also issued estimates for Nicox’s Q4 2026 earnings at $0.11 EPS.

Separately, Zacks Research upgraded Nicox to a “hold” rating in a research note on Friday, October 10th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Nicox Price Performance

OTCMKTS NICXF opened at $0.30 on Wednesday. The business’s 50-day moving average is $0.30 and its 200 day moving average is $0.29. Nicox has a 1 year low of $0.25 and a 1 year high of $0.30.

Nicox Company Profile

Nicox is a global biopharmaceutical company focused on the research, development and commercialization of innovative treatments for eye diseases. The company’s therapeutic approach centers on nitric oxide–donating compounds and anti-inflammatory agents designed to address glaucoma, ocular surface disorders and allergic eye conditions. With a pipeline spanning pre-clinical to late-stage clinical programs, Nicox aims to bring new modalities to market that target unmet needs in ophthalmology.

The company’s lead commercial product, ZERVIATE® (ciclesonide ophthalmic solution), is indicated for the relief of ocular itching associated with allergic conjunctivitis.